Biotech Stocks' Research Reports Released on CorMedix, Curis, Cyclacel Pharma, and Cymabay Therapeutics

Wednesday, March 21, 2018 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, March 21, 2018 /PRNewswire/ --

WallStEquities.com strives to bring the best free research to the investment

community.  Today we are offering reports on CRMD, CRIS, CYCC, and CBAY which can be accessed for free by signing up to www.wallstequities.com/registration. On Tuesday, the NASDAQ Composite ended the day at 7,364.30, up 0.27%; the Dow Jones Industrial
Average edged 0.47% higher, to finish at 24,727.27; and the S&P 500 closed at 2,716.94, marginally gaining 0.15%. Gains were broad based as six out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: CorMedix Inc. (NYSE AMER: CRMD), Curis Inc. (NASDAQ: CRIS), Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC), and Cymabay Therapeutics Inc. (NASDAQ: CBAY). All you have to do is sign up today for this free limited time offer by clicking the link below. www.wallstequities.com/registration

CorMedix

Bridgewater, New Jersey-based CorMedix Inc.'s stock finished Tuesday's session 12.63% lower at $0.25 with a total trading volume of 5.22 million shares, which was higher than their three months average volume of 1.63 million shares. The Company's shares are trading below their 50-day moving average by 39.98%. Moreover, shares of CorMedix, which focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the US and other markets, have a Relative Strength Index (RSI) of 29.58. Get the full research report on CRMD for free by clicking below at: www.wallstequities.com/registration/?symbol=CRMD

Curis

Shares in Lexington, Massachusetts headquartered Curis Inc. declined 3.30%, ending yesterday's session at $0.71 with a total trading volume of 1.46 million shares. The stock has gained 29.29% in the past month. The Company's shares are trading above their 50-day moving average by 10.07%. Moreover, shares of Curis, which focuses on the development and commercialization of drug candidates for the treatment of human cancers in the US, have an RSI of 52.63. Gain free access to the research report on CRIS at: www.wallstequities.com/registration/?symbol=CRIS

Cyclacel Pharmaceuticals

On Tuesday, Berkeley Heights, New Jersey headquartered Cyclacel Pharmaceuticals Inc.'s stock saw a drop of 1.64%, to close the day at $1.50. A total volume of 91,791 shares was traded. The stock is trading below its 50-day moving average by 8.22%. Additionally, shares of Cyclacel Pharma, which develops medicines for the treatment of cancer and other proliferative diseases, have an RSI of 37.31. Register for your free report coverage on CYCC at: www.wallstequities.com/registration/?symbol=CYCC

Cymabay Therapeutics

Shares in Newark, California headquartered Cymabay Therapeutics Inc. ended the day 2.44% lower at $13.20. A total volume of 650,353 shares was traded. The stock has gained 58.65% in the previous three months and 225.12% over the last twelve months. The Company's shares are trading above their 50-day and 200-day moving averages by 4.99% and 52.96%, respectively. Furthermore, shares of Cymabay Therapeutics, which focuses on developing and commercializing therapies to treat specialty and orphan diseases, have an RSI of 47.47. Get the free research report on CBAY at: www.wallstequities.com/registration/?symbol=CBAY

Wall St. Equities

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

 

Cision View original content:http://www.prnewswire.com/news-releases/biotech-stocks-research-reports-released-on-cormedix-curis-cyclacel-pharma-and-cymabay-therapeutics-300617380.html

SOURCE Wall St. Equities

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store